Helping T cells resist exhaustion during long-term infections
Resistance to T cell exhaustion
Looks at ways to keep immune T cells working in people with chronic viral infections so treatments like checkpoint blockers work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11160635 on NIH RePORTER |
What this research studies
Researchers are studying how signals from the immune protein IL-2 and supportive CD4 helper T cells shape the fate of CD8 'killer' T cells during long-term viral infections. They combine lab experiments that follow T cell behavior with models of chronic infection and tests of checkpoint-blockade therapies to see which cells resist becoming exhausted. The team also examines cells transferred between animals (adoptive transfer) and how early IL-2-producing T cells influence later protection. Findings aim to point toward strategies that could be turned into better therapies to control long-term viruses without causing harmful inflammation.
Who could benefit from this research
Good fit: Ideal candidates would be people living with chronic viral infections or those receiving therapies that target exhausted T cells who might later join related clinical tests.
Not a fit: People with short-term (acute) infections or conditions not driven by T cell exhaustion are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to boost patient immune responses and improve outcomes for people with chronic viral infections or those receiving immunotherapies.
How similar studies have performed: Related laboratory and animal studies have shown promising signals that IL-2-producing T cells can resist exhaustion and improve control, but translating these findings into human therapies remains novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Zajac, Allan J — University of Alabama at Birmingham
- Study coordinator: Zajac, Allan J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.